Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Applied Molecular Transport Inc.AMTI · Entity 95737 | Director | May 24, 2022 | May 26, 2022 |
| Lucira Health, Inc.LHDX · Entity 115613 | Director | June 01, 2022 | June 03, 2022 |
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Applied Molecular Transport Inc.
Report date May 24, 2022 · Filed May 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 · Expires 2032-05-24 | Direct | 20,000 |
Reported balance
After 2022-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-24 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the stock option granted on May 24, 2022 will become vested on the earlier of (i) May 24, 2023 or (ii) the business day prior to the date of the 2023 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the stock option granted on May 24, 2022 will become vested on the earlier of (i) May 24, 2023 or (ii) the business day prior to the date of the 2023 annual meeting of stockholders.
Lucira Health, Inc.
Report date June 01, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2032-05-31 | Direct | 59,459 |
Reported balance
After 2022-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 59,459 · Balance 59,459 F1: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting.
Quince Therapeutics, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-06-11 | Direct | 2,700 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 2,700 · Balance 2,700 F1: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:57 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000912282-26-000832 · form4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,700 Underlying: Common Stock · 2,700 shares Expires 2036-06-11 F1 · derivative.exercise_date: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Read SEC document |
| January 02, 2026 Filed Jan 21, 2026 23:05 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 29,423 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000085 · form4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,423 Underlying: Common Stock · 29,423 shares Expires 2036-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:33 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000619 · form4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2025 Filed Jan 9, 2025 00:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (right to buy) · Derivative | 47,587 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001415889-25-001162 · form4-01092025_120154.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,587 Underlying: Common Stock · 47,587 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 05, 2024 Filed Jun 8, 2024 01:08 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001415889-24-016093 · form4-06082024_010656.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Read SEC document |
| December 14, 2023 Filed Dec 14, 2023 23:21 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 22,627 | $1.04 | $23,532.08 |
DisclosureSEC source: 0001209191-23-058694 · doc4.xml · nonDerivative · entry 4 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,347,545 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 23:21 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 22,627 | $1.00 | $22,627.00 |
DisclosureSEC source: 0001209191-23-058694 · doc4.xml · nonDerivative · entry 3 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,324,918 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.99 to $1.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range. F1 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 23:21 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 22,327 | $1.02 | $22,773.54 |
DisclosureSEC source: 0001209191-23-058694 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,302,291 Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 23:21 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 300 | $1.00 | $300.00 |
DisclosureSEC source: 0001209191-23-058694 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,279,964 F1 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| December 07, 2023 Filed Dec 7, 2023 23:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 19,123 | $1.01 | $19,314.23 |
DisclosureSEC source: 0001209191-23-057799 · doc4.xml · nonDerivative · entry 3 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,279,664 F1 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 23:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 19,123 | $1.02 | $19,505.46 |
DisclosureSEC source: 0001209191-23-057799 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,260,541 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.99 to $1.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range. F1 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 23:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 19,123 | $1.01 | $19,314.23 |
DisclosureSEC source: 0001209191-23-057799 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,241,418 F1 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| December 01, 2023 Filed Dec 1, 2023 18:38 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 14,378 | $0.94 | $13,515.32 |
DisclosureSEC source: 0001209191-23-057053 · doc4.xml · nonDerivative · entry 3 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,222,295 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.91 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 18:38 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 14,378 | $0.90 | $12,940.20 |
DisclosureSEC source: 0001209191-23-057053 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,207,917 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 18:38 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 14,378 | $0.98 | $14,090.44 |
DisclosureSEC source: 0001209191-23-057053 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,193,539 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 22:42 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 41,026 | $1.32 | $54,154.32 |
DisclosureSEC source: 0001209191-23-047880 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,179,161 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 22:42 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 41,026 | $1.31 | $53,744.06 |
DisclosureSEC source: 0001209191-23-047880 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,138,135 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.30 to $1.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| August 17, 2023 Filed Aug 17, 2023 22:08 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 24,766 | $1.29 | $31,948.14 |
DisclosureSEC source: 0001209191-23-046402 · doc4.xml · nonDerivative · entry 3 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,097,109 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.28 to $1.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 22:08 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 117,348 | $1.29 | $151,378.92 |
DisclosureSEC source: 0001209191-23-046402 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 2,072,343 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.26 to $1.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 22:08 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 107,886 | $1.32 | $142,409.52 |
DisclosureSEC source: 0001209191-23-046402 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,954,995 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.26 to $1.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:47 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-23-032674 · doc4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 00:43 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001209191-22-035672 · doc4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 8, 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:38 UTC | Lucira Health, Inc. LHDX · Entity 115613 | GrantStock Option (right to buy) · Derivative | 59,459 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001209191-22-034086 · doc4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,459 Underlying: Common Stock · 59,459 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:17 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001209191-22-032263 · doc4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-24 F1 · derivative.exercise_date: 100% of the stock option granted on May 24, 2022 will become vested on the earlier of (i) May 24, 2023 or (ii) the business day prior to the date of the 2023 annual meeting of stockholders. Read SEC document |
| May 23, 2022 Filed May 23, 2022 18:18 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | PurchaseCommon Stock | 33,500 | $3.26 | $109,210.00 |
DisclosureSEC source: 0001209191-22-031435 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,077,519 F3 · price: The price reported in column is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.15 to $3.32, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held directly by the Blue Devil Trust for which the Reporting Person serves as trustee. Read SEC document |
| May 20, 2022 Filed May 23, 2022 18:18 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | PurchaseCommon Stock | 33,000 | $3.08 | $101,640.00 |
DisclosureSEC source: 0001209191-22-031435 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,044,019 F1 · price: The price reported in column is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.03 to $3.14, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held directly by the Blue Devil Trust for which the Reporting Person serves as trustee. Read SEC document |
| May 19, 2022 Filed May 24, 2022 00:09 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantCommon Stock | 200,002 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-031500 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David A. Lamond Trust dated 2006 Disclosed balance after: 1,734,722 F1 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. F2 · ownership.nature: Mr. Lamond is the trustee of David A. Lamond Trust dated 2006 (the "2006 Trust") and holds sole voting and dispositive power with respect to the shares held of record by the 2006 Trust. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:25 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 11,029 | $0.00 Strike: $50.56 | $0.00 |
DisclosureSEC source: 0001209191-21-041711 · doc4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,029 Underlying: Common Stock · 11,029 shares Expires 2031-06-15 F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 16, 2021. Read SEC document |
| May 18, 2021 Filed May 20, 2021 19:05 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantStock Option (Right to Buy) · Derivative | 15,175 | $0.00 Strike: $47.01 | $0.00 |
DisclosureSEC source: 0001209191-21-034608 · doc4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,175 Underlying: Common Stock · 15,175 shares Expires 2031-05-18 F1 · derivative.exercise_date: 100% of the stock option granted on May 18, 2021 will become vested on the earlier of (i) May 18, 2022 or (ii) the business day prior to the date of the 2022 annual meeting of stockholders. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 18:47 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | PurchaseCommon Stock | 25,000 | $42.00 | $1,050,000.00 |
DisclosureSEC source: 0001209191-21-025973 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,011,019 F1 · ownership.nature: The shares are held directly by the Blue Devil Trust for which the Reporting Person serves as trustee, and holds voting and dispositive power. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 01:06 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 50,000 | $33.77 | $1,688,500.00 |
DisclosureSEC source: 0001209191-21-022947 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,847,109 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.51 to $33.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:54 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 4,100 | $36.86 | $151,126.00 |
DisclosureSEC source: 0001209191-21-018328 · doc4.xml · nonDerivative · entry 4 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,797,109 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $36.76 to $36.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:54 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 15,969 | $36.34 | $580,313.46 |
DisclosureSEC source: 0001209191-21-018328 · doc4.xml · nonDerivative · entry 3 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,793,009 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.75 to $36.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:54 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 13,310 | $35.00 | $465,850.00 |
DisclosureSEC source: 0001209191-21-018328 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,777,040 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.75 to $35.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:54 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 16,621 | $34.28 | $569,767.88 |
DisclosureSEC source: 0001209191-21-018328 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,763,730 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.75 to $34.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| March 04, 2021 Filed Mar 23, 2021 23:13 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GiftCommon Stock | 1,534,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-022688 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David A. Lamond Trust dated 2006 Disclosed balance after: 1,534,720 F1 · kind: On March 4, 2021, in accordance with the provisions of a Grantor Retained Annuity Trust (the "GRAT"), 1,534,720 shares were distributed from the GRAT to the David A. Lamond Trust dated 2006 for the benefit of the Reporting Person. F2 · ownership.nature: Mr. Lamond is the trustee of David A. Lamond Trust dated 2006 (the "2006 Trust") and holds sole voting and dispositive power with respect to the shares held of record by the 2006 Trust. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 19:50 UTC | Lucira Health, Inc. LHDX · Entity 115613 | ConversionSeries C Preferred Stock · Derivative | 92,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009039 · doc4.xml · derivative · entry 5 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: 02/09/2021 · 92,756 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by Blue Devil Trust, for which Mr. Lamond serves as a trustee. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 19:50 UTC | Lucira Health, Inc. LHDX · Entity 115613 | ConversionSeries B Preferred Stock · Derivative | 53,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009039 · doc4.xml · derivative · entry 4 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: 02/09/2021 · 53,629 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by Blue Devil Trust, for which Mr. Lamond serves as a trustee. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 19:50 UTC | Lucira Health, Inc. LHDX · Entity 115613 | ConversionCommon Stock | 92,756 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009039 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 146,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by Blue Devil Trust, for which Mr. Lamond serves as a trustee. Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 19:50 UTC | Lucira Health, Inc. LHDX · Entity 115613 | ConversionCommon Stock | 53,629 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009039 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 53,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock") automatically converted on a one-for-one basis into Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by Blue Devil Trust, for which Mr. Lamond serves as a trustee. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 18:38 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | ConversionSeries C Preferred Stock · Derivative | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036057 · doc4.xml · derivative · entry 5 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into one share of issuer's common stock immediately prior to the closing of the issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into one share of issuer's common stock immediately prior to the closing of the issuer's initial public offering. F3 · derivative.expiration_date: The shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by the Blue Devil Trust for which Mr. Lamond serves as trustee and over which shares Mr. Lamond holds voting and dispositive power. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 18:38 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | ConversionSeries B Preferred Stock · Derivative | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036057 · doc4.xml · derivative · entry 4 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into one share of issuer's common stock immediately prior to the closing of the issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into one share of issuer's common stock immediately prior to the closing of the issuer's initial public offering. F3 · derivative.expiration_date: The shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by the Blue Devil Trust for which Mr. Lamond serves as trustee and over which shares Mr. Lamond holds voting and dispositive power. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 18:38 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | ConversionSeries A Preferred Stock · Derivative | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036057 · doc4.xml · derivative · entry 3 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into one share of issuer's common stock immediately prior to the closing of the issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into one share of issuer's common stock immediately prior to the closing of the issuer's initial public offering. F3 · derivative.expiration_date: The shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by the Blue Devil Trust for which Mr. Lamond serves as trustee and over which shares Mr. Lamond holds voting and dispositive power. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 18:38 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantCommon Stock | 71,430 | $14.00 | $1,000,020.00 |
DisclosureSEC source: 0001209191-20-036057 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 986,019 F2 · ownership.nature: The shares are held directly by the Blue Devil Trust for which Mr. Lamond serves as trustee and over which shares Mr. Lamond holds voting and dispositive power. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 18:38 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | ConversionCommon Stock | 914,589 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036057 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 914,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into one share of issuer's common stock immediately prior to the closing of the issuer's initial public offering. F2 · ownership.nature: The shares are held directly by the Blue Devil Trust for which Mr. Lamond serves as trustee and over which shares Mr. Lamond holds voting and dispositive power. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 00:12 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 11,029 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0001209191-20-035419 · doc4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,029 Underlying: Common Stock · 11,029 shares Expires 2030-06-07 F1 · derivative.exercise_date: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 22:47 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 24,874 | $43.88 | $1,091,384.06 |
DisclosureSEC source: 0001209191-20-035104 · doc4.xml · nonDerivative · entry 3 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,747,109 F4 · price: The range of prices for the shares of Common Stock is from $43.61 to $44.10. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 22:47 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 10,642 | $43.32 | $461,033.79 |
DisclosureSEC source: 0001209191-20-035104 · doc4.xml · nonDerivative · entry 2 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,722,235 F3 · price: The range of prices for the shares of Common Stock is from $42.61 to $43.60. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 22:47 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 13,609 | $42.13 | $573,377.11 |
DisclosureSEC source: 0001209191-20-035104 · doc4.xml · nonDerivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,711,593 F1 · price: The range of prices for the shares of Common Stock is from $41.58 to $42.55. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
| May 19, 2020 Filed May 19, 2020 22:41 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 32,894 | $56.42 | $1,855,738.04 |
DisclosureSEC source: 0001209191-20-030688 · doc4.xml · nonDerivative · entry 9 Lamond David · CIK 0001770790 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Blue Devil Trust dated 12/03/2010 Disclosed balance after: 1,697,984 F9 · price: The range of prices for the shares of Common Stock is from $55.90 to $56.87. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. F2 · ownership.nature: Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.